Posted by Michael Wonder on 09 Jan 2019
Biotech proposes paying for pricey drugs by instalment
8 January 2019 - Bluebird Bio develops plan to sell gene-replacement therapy with annual payments contingent on continued effectiveness.
A Boston-area biotech says it may have a found a way to handle the expected seven-figure cost of its experimental gene therapy: paying on instalment.
Bluebird Bio is developing plans to sell its first gene-replacement therapy, for a rare inherited blood disease, on a five-year instalment plan, with each annual payment contingent on its treatment’s continued effectiveness.
